Pennsylvania Trust Co acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 65,696 shares of the biopharmaceutical company’s stock, valued at approximately $12,481,000. Pennsylvania Trust Co owned approximately 0.06% of Alnylam Pharmaceuticals as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Panagora Asset Management Inc. grew its position in Alnylam Pharmaceuticals by 31.4% in the third quarter. Panagora Asset Management Inc. now owns 4,094 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 979 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Alnylam Pharmaceuticals by 768.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,145 shares in the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in Alnylam Pharmaceuticals by 55.2% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 3,724 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 1,324 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Alnylam Pharmaceuticals by 6,519.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 213,065 shares of the biopharmaceutical company’s stock valued at $18,648,000 after buying an additional 209,846 shares during the period. Finally, Pacer Advisors Inc. bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $231,000. 86.88% of the stock is owned by institutional investors.
Several equities research analysts recently issued reports on ALNY shares. Cowen reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 6th. BidaskClub upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 1st. Needham & Company LLC reiterated a “buy” rating and set a $135.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, February 8th. Cantor Fitzgerald restated a “buy” rating and set a $135.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday, February 7th. Finally, ValuEngine downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $128.39.
Alnylam Pharmaceuticals stock opened at $88.56 on Wednesday. The stock has a market cap of $9.41 billion, a price-to-earnings ratio of -11.70 and a beta of 2.61. The company has a quick ratio of 6.56, a current ratio of 6.69 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals, Inc. has a 52-week low of $60.27 and a 52-week high of $124.21.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 7th. The biopharmaceutical company reported ($2.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.27) by $0.18. The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $18.03 million. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The firm’s revenue was down 44.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.20) EPS. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -8.68 earnings per share for the current fiscal year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
See Also: Understanding Options Trading
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.